

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:	tba	Art Unit:	tba
Filed:	tba	Examiner:	tba
1 st Inventor:	A. Fujishima	Allowed:	
For:	Benzimidazole Compound Crystal	Batch:	
Atty. Dkt. No.	2635 US2P	Paper No.:	

Information Disclosure Statement

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR §1.56, 1.97 and 1.98, applicants request consideration of the reference listed on the attached form PTO-1449. A legible copy of the listed reference is herewith being provided to the Examiner.

In accordance with the recent change in the rules, copies of U.S. patents cited on Form PTO 1449 have not been submitted.

Should the Examiner believe that a conference with applicants' attorney would advance prosecution of this application, the Examiner is respectfully requested to call applicants' attorney at (847) 383-3391.

Respectfully submitted,

Dated: 9/4/03

(847) 383-3391
(847) 383-3372

Elaine M Ramesh
Elaine M. Ramesh, Ph.D., Reg. No. 43,032
Mark Chao, Ph.D., Reg. No. 37,293
Attorney for Applicants
Customer No. 23115

Takeda Pharmaceuticals North America, Inc.
Intellectual Property Department
Suite 500, 475 Half Day Road
Lincolnshire, IL 60069 USA

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
LIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)

Date Submitted to PTO:

ATTY DOCKET NO.:
2635 US2P

SERIAL NO.:
tba

APPLICANT: A. Fujishima

FILING DATE:
tba

GROUP: tba
Examiner: tba

*EXAMINER INITIAL	REF No.	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		4,628,098	12/9/1986	A. Nohara, et al.			

*EXAMINER INITIAL	REF No.	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
		WO 97/02261	01/23/1997	WIPO			
		WO 96/02535	02/01/1996	WIPO			
		WO 99/38512	08/05/1999	WIPO			
		WO 92/08716	5/29/1992	WIPO			Yes - Abstract only
		WO 99/38513	8/5/1999	WIPO			
		WO 96/17077	6/6/1996	WIPO			
		WO 98/21201	5/22/1998	WIPO			
		EP 0302720	2/8/1989	EP			
		EP 0174726	3/19/1986	EP			

*EXAMINER INITIAL	REF No.	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
		Nagaya, et al. "Effects of the Enantiomers of Lansoprazole (AG-1749) on (H ⁺ + K ⁺)-ATPase Activity in Canine Gastric Microsomes and Acid Formation in Isolated Canine Parietal Cells" Biochemical Pharmacology 42(10): 1875-1878 (1991)
		Čurin, et al. "Study of Crystal Modifications of Lansoprazole Using FT-IR Spectroscopy, solid-State NMR Spectroscopy and FT-Raman Spectroscopy" Farm vesn 48: 290-291 (1997)
		Katsuki, et al. "Determination of R(+) and S(-)-Lansoprazole Using Chiral Stationary-Phase Liquid Chromatography and Their Enantioselective Pharmacokinetics in Humans" Pharmaceutical Research 13(4):611-615 (1996)
		Vrečer, et al. "Study of Influence of Temperature and Grinding on the Crystalline State of Lansoprazole" Farm vestn 48:242-243 (1997)

EXAMINER:

DATE CONSIDERED:

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.